Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 9 - Drugs for disorders of the cardiovascular system
Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
10/2002
10/03/2002WO2002076446A1 Esmolol formulation
10/03/2002WO2002076443A1 Use of breakers of advanced glycation endproducts for treating deleterious effects of aging and debilitating diseases
10/03/2002WO2002076438A2 Flt-1 ligands and their uses in the treatment of diseases regulatable by angiogenesis
10/03/2002WO2002076435A2 Lipid profile modulation with steroids
10/03/2002WO2002076405A2 Compositions and methods of treatment of ulcerating diseases, burns, and related conditions
10/03/2002WO2002076404A2 Fatty alcohol drug conjugates
10/03/2002WO2002076402A2 Fatty amine drug conjugates
10/03/2002WO2002076400A2 Inosine compounds and their use for treating or preventing an inflamation or a reperfusion disease
10/03/2002WO2002076376A2 A stable pharmaceutical composition of pravastatin
10/03/2002WO2002076196A1 Transgenic animals expressing antibodies specific for genes of interest and uses thereof
10/03/2002WO2002065834A3 Novel formulations of carvedilol
10/03/2002WO2002062784A8 Piperidinee derivatives as neurokinin 1 antagonists
10/03/2002WO2002062293A3 Coumarin compounds as microtubule stabilizing agents and therapeutic uses thereof
10/03/2002WO2002059153A3 Anticoagulants and their uses
10/03/2002WO2002022677A3 Variants of allergenic proteins of the group 2 of dermatophagoides
10/03/2002WO2002014349A3 Non-covalent inhibitors of urokinase and blood vessel formation
10/03/2002WO2001089543A3 Use of proanthocyanidins as an active ingredient of a stimulator and l-arginine or its salts as a source of nitric oxide to relieve symptoms of erectile dysfuntion
10/03/2002WO2001071004A3 Proteases
10/03/2002WO2001021812A9 Phosphatases which activate map kinase pathways
10/03/2002WO2001021106A9 Radioactive graft or cuff
10/03/2002WO2001017508A9 Cationic liposome delivery of taxanes to angiogenic blood vessels
10/03/2002US20020143187 Nitric oxide donors and pharmaceutical compositions containing them
10/03/2002US20020143162 Methods
10/03/2002US20020143149 Seven trans-membrane receptor-Fitz2
10/03/2002US20020143145 Detcting moduators of binding activity of preferential membrane proteins; obtain animal, incubate with modulator, monitor adjustment in activity from recptors
10/03/2002US20020143064 Inhibiting vascularization of a tumor mass by administering chalcone compound
10/03/2002US20020143048 Method for treating atherosclerosis or restenosis using microtubule stabilizing agent
10/03/2002US20020143045 Reacting 4-(oxiran-2-ylmethoxy)-9H- carbazole with 2-(2-methoxyphenoxy)ethylamine to produce carvedilol
10/03/2002US20020143043 For therapy and prophylaxis of rheumatoid arthritis, or of allergic disorders, asthma, inflammation; inhibitors of the adhesion and migration of leucocytes and/or antagonists of adhesion receptor VLA-4 belonging to the integrins group
10/03/2002US20020143036 Pentafluorobenzenesulfonamides and analogs
10/03/2002US20020143032 Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
10/03/2002US20020143027 As inhibitors of tumor necrosis factor; for therapy of cachexia, arthritis, rheumatoid arthritis, osteoarthritis, reperfusion injury, congestive heart failure, Crohn's disease, ulcerative colitis, systemic lupus erythrematosis
10/03/2002US20020143026 Induce mitotic arrest thereby making them useful as anti-cancer agents; also for therapy of diseases which can be treated by inducing mitotic arrest
10/03/2002US20020143020 Novel piperazine derivatives
10/03/2002US20020143017 Pyridazinone aldose reductase inhibitors
10/03/2002US20020143008 CRF receptor antagonists and methods relating thereto
10/03/2002US20020143004 Allosteric adenosine receptor modulators
10/03/2002US20020142996 Use of bisphosphonic acids for treating angiogenesis
10/03/2002US20020142995 To enhance the ability of mammalian red blood cells to deliver oxygen, by delivering ligand for the allosteric site of hemoglobin to the cytoplasm of the red blood cells
10/03/2002US20020142983 MUC-1 antagonists and methods of treating immune disorders
10/03/2002US20020142968 For therapeutic and/or prophylactic treatment of idiopathic and adult respiratory distress syndrome, pulmonary fibrosis following treatment with radiation or chemotherapy, septic shock, septicemia, inflammatory responses
10/03/2002US20020142436 Enzymatic protein for use in the treatment of tumors, nervous system, cardiovascular, psychological, pregnancy, bone, kidney, respiratory and alimentary canal disorders
10/03/2002US20020142432 Human endosulfine gene
10/03/2002US20020142430 Peptide for use in the treatment of inflammation, cancer, arteriosclerosis and psoriasis
10/03/2002US20020142353 Connective tissue growth factor (CTGF) and methods of use
10/03/2002US20020142330 Novel glutamate receptor modulatory proteins and nucleic acid molecules and uses therefor
10/03/2002US20020142283 Inhibitors of C-reactive protein induced inflammation
10/03/2002US20020142045 Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect
10/03/2002US20020142029 Use of complexes among cationic liposomes and polydeoxyribonucleotides and medicaments
10/03/2002US20020141992 Deactivation of collagen receptors
10/03/2002US20020141987 Fish serine proteinases and their pharmaceutical and cosmetic use
10/03/2002US20020141985 Dietetics, eating disorders, antidiabetic agents
10/03/2002US20020141977 Immunotherapy based on dendritic cells
10/03/2002CA2442280A1 A stable pharmaceutical composition of pravastatin
10/03/2002CA2442178A1 2-amino-propanol derivatives
10/03/2002CA2442080A1 A preparation for restenosis prevention
10/03/2002CA2441806A1 Inosine compounds and their use for treating or preventing an inflammation or a reperfusion disease
10/03/2002CA2441790A1 1,2,3,4-tetrahydroisoquinolines derivatives as urotensin ii receptor antagonists
10/03/2002CA2441599A1 Fused pyridine derivatives for use as vanilloid receptor antagonists for treating pain
10/03/2002CA2441378A1 Nucleic acid molecules encoding serine protease cvsp14, the encoded polypeptides and methods based thereon
10/03/2002CA2441092A1 Dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
10/03/2002CA2440676A1 Transgenic animals expressing antibodies specific for genes of interest and uses thereof
10/03/2002CA2440389A1 Aminopyrrolidine sulfonamides as serine protease inhibitors
10/03/2002CA2436351A1 3,4-di-substituted cyclobutene-1, 2-diones as cxc chemokine receptor antagonists
10/03/2002CA2436340A1 Histidine-rich glycoprotein
10/03/2002CA2436198A1 Process for obtaining lignan, pharmaceutical compositions and uses thereof
10/03/2002CA2434691A1 Use of propentofylline to control intraocular pressure
10/02/2002WO2001076587A1 Remedies for diseases due to stenotic lesions of blood vessel
10/02/2002EP1245676A1 Human monoclonal antibodies against tgf-beta ii receptor and medicinal use thereof
10/02/2002EP1245564A1 Benzamidine derivatives
10/02/2002EP1245562A1 5-THIA-$g(v)-(SUBSTITUTED PHENYL)-PROSTAGLANDIN E ALCOHOLS, PROCESS FOR PREPARING THE ALCOHOLS AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME AS THE ACTIVE INGREDIENT
10/02/2002EP1245561A1 N-substituted benzyl or phenyl aromatic sulfamides compounds and the use thereof
10/02/2002EP1245229A2 Methods and compositions for inhibition of angiogenesis
10/02/2002EP1244915A2 Method for identifying inhibitors of cytokinesis
10/02/2002EP1244790A2 Nucleic acids encoding polypeptides having chips activity
10/02/2002EP1244774A2 Pak5 a member of the p21-activated kinase (pak) protein family, nucleic acids and methods related to the same
10/02/2002EP1244700A2 Vesicle trafficking proteins
10/02/2002EP1244693A1 Compositions for treating abnormalities in glomerular filtration, patent ductus arteriosus and osteoporosis
10/02/2002EP1244683A1 21 human secreted proteins
10/02/2002EP1244678A1 Phosphonic acid derivatives as inhibitors of protein tyrosine phosphatase 1b (ptp-1b)
10/02/2002EP1244677A1 Phosphonic acid biaryl derivatives as inhibitors of protein tyrosine phosphatase 1b (ptp-1b)
10/02/2002EP1244673A2 Novel imidazo 1,3,5]triazinones and the use thereof
10/02/2002EP1244672A1 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors
10/02/2002EP1244669A1 Pyrazolopyrazines and their use as adenosine antagonists
10/02/2002EP1244666A1 Imidazopyrimidinyl and imidazopyridinyl derivatives
10/02/2002EP1244657A2 Sulfonamides and derivatives thereof that modulate the activity of endothelin
10/02/2002EP1244653A1 Non peptide tachykinin receptor antagonists
10/02/2002EP1244649A1 Cyclic amp-specific phosphodiesterase inhibitors
10/02/2002EP1244647A1 Quinazoline derivatives as vegf inhibitors
10/02/2002EP1244642A1 Substituted oxazoles and thiazoles derivatives as hppar alpha activators
10/02/2002EP1244640A1 Oxazolidinone derivatives
10/02/2002EP1244631A1 New azabicyclooctane derivatives useful in the treatment of cardiac arrhythmias
10/02/2002EP1244628A1 Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
10/02/2002EP1244626A2 Caspase inhibitors and uses thereof
10/02/2002EP1244621A1 Nitrile derivatives as cathepsin k inhibitors
10/02/2002EP1244620A1 Cyclic amp-specific phosphodiesterase inhibitors
10/02/2002EP1244619A1 Pyrrolidines which inhibit camp-specific pde
10/02/2002EP1244616A1 (hetero)bicyclylmethanesulfonylamino-substituted hydroxamic acid derivatives
10/02/2002EP1244461A2 INHIBITION OF GSK-3$g(b)
10/02/2002EP1244455A1 Methods of treating vascular diseases characterized by nitric oxide insufficiency
1 ... 1085 1086 1087 1088 1089 1090 1091 1092 1093 1094 1095 1096 1097 1098 1099 1100 1101 1102 1103 1104 1105 ... 1595